Papers
1
Total Citations
16
H-Index
1
About
M. G. Berger is a hematologist-oncologist whose research focuses on the intricate interplay between chronic myeloid leukemia (CML) and other myeloproliferative neoplasms (MPNs), particularly in the context of targeted therapy. His most notable contribution is the identification and characterization of a rare but clinically significant phenomenon: the emergence of a JAK2V617F-positive MPN in patients with Philadelphia-positive CML who achieve molecular remission on imatinib. In his 2009 paper, which has garnered 16 citations, Berger demonstrated that a thrombocytosis occurring during imatinib response can signal an underlying JAK2V617F mutation, rather than treatment failure or disease progression. This work has profound implications for patient management, as it highlights the need for vigilant monitoring and differential diagnosis in CML patients with unexpected platelet elevations. Berger’s findings bridge a critical gap in understanding clonal evolution and therapy-related secondary neoplasms, offering a nuanced perspective on the dynamic nature of hematological malignancies. His research underscores the importance of molecular profiling in guiding personalized treatment strategies, making him a key voice in the field of myeloid neoplasms.
Research Focus
Key Achievements
Top Papers
- 1